{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:00:12Z","timestamp":1785859212988,"version":"3.56.0"},"update-to":[{"DOI":"10.1002\/14651858.cd015005","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000}}],"reference-count":135,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015005.pub2","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T06:46:55Z","timestamp":1733726815000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Azathioprine for people with multiple sclerosis"],"prefix":"10.1002","volume":"2024","author":[{"given":"Ben","family":"Ridley","sequence":"additional","affiliation":[{"name":"IRCCS Istituto delle Scienze Neurologiche di Bologna; Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Nonino","sequence":"additional","affiliation":[{"name":"IRCCS Istituto delle Scienze Neurologiche di Bologna; Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Baldin","sequence":"additional","affiliation":[{"name":"IRCCS Istituto delle Scienze Neurologiche di Bologna; Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Casetta","sequence":"additional","affiliation":[{"name":"IRCCS San Camillo Hospital; Venice Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Iuliano","sequence":"additional","affiliation":[{"name":"UO Neurologia; Ospedali Riuniti di Salerno; Salerno Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Filippini","sequence":"additional","affiliation":[{"name":"Scientific Director\u2019s Office; Carlo Besta Foundation and Neurological Institute; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD015005.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1212\/wnl.43.4.831","article-title":"Long-term safety of azathioprine therapy in multiple sclerosis","volume":"43","author":"Amato","year":"1993","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0002|cit2","first-page":"179","article-title":"Double-masked trial of azathioprine in multiple sclerosis","volume":"2","author":"British and Dutch Multiple Sclerosis Azathioprine Trial Group","year":"1988","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD015005.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/jnnp.50.10.1387","article-title":"Double-blind controlled trial of azathioprine in the treatment of multiple sclerosis","volume":"50","author":"British and Dutch Multiple Sclerosis Azathioprine Trial","year":"1987","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s0303-8467(88)80005-2","article-title":"A long-term double-blind controlled study on the effect of azathioprine in the treatment of multiple sclerosis","volume":"90","author":"Minderhoud","year":"1988","journal-title":"Clinical Neurology and Neurosurgery"},{"issue":"2","key":"10.1002\/14651858.CD015005.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1046\/j.1351-5101.2003.00721.x","article-title":"The risk of cancer from azathioprine as a treatment for multiple sclerosis","volume":"11","author":"Taylor","year":"2004","journal-title":"European Journal of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD015005.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1212\/wnl.46.6.1607","article-title":"Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study","volume":"46","author":"Confavreux","year":"1996","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1212\/wnl.39.8.1018","article-title":"A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis","volume":"39","author":"Ellison","year":"1989","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD015005.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00415-007-0637-1","article-title":"Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis","volume":"254","author":"Etemadifar","year":"2007","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1212\/wnl.41.1.20","article-title":"The efficacy of azathioprine in relapsing-remitting multiple sclerosis","volume":"41","author":"Goodkin","year":"1991","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD015005.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1177\/1352458509105229","article-title":"Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis","volume":"15","author":"Havrdova","year":"2009","journal-title":"Multiple Sclerosis"},{"issue":"4","key":"10.1002\/14651858.CD015005.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/jnnp.2007.120378","article-title":"Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study","volume":"79","author":"Horakova","year":"2008","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"1-2","key":"10.1002\/14651858.CD015005.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jns.2008.12.005","article-title":"Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study","volume":"282","author":"Horakova","year":"2009","journal-title":"Journal of the Neurological Sciences"},{"issue":"7","key":"10.1002\/14651858.CD015005.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.clineuro.2012.02.014","article-title":"Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort","volume":"114","author":"Kalincik","year":"2012","journal-title":"Clinical Neurology and Neurosurgery"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0014|cit14","unstructured":"Assessment of lesion activity analysis in the avonex-steroid azathioprine (ASA) Study (ASA) https:\/\/clinicaltrials.gov\/study\/NCT01628315"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0015|cit15","first-page":"516","article-title":"Cyclosporin A versus azathioprine in multiple sclerosis: seven year follow-up and long-term side effects","volume":"57","author":"Haas","year":"1994","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD015005.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/ana.410230110","article-title":"Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis - results of the German multicenter study","volume":"23","author":"Kappos","year":"1988","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD015005.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/BF00328179","article-title":"Magnetic resonance imaging in the evaluation of treatment in multiple sclerosis","volume":"30","author":"Kappos","year":"1988","journal-title":"Neuroradiology"},{"issue":"1","key":"10.1002\/14651858.CD015005.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/BF02190090","article-title":"A 10-year matched-pairs study comparing azathioprine and no immunosuppression in multiple sclerosis","volume":"240","author":"Kappos","year":"1990","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"e113371","DOI":"10.1371\/journal.pone.0113371","article-title":"Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial","volume":"9","author":"Massacesi","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1002\/14651858.CD015005.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/BF02334408","article-title":"Double blind controlled randomized study on azathioprine efficacy in multiple sclerosis. Preliminary results","volume":"9","author":"Milanese","year":"1988","journal-title":"Italian Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/BF00838165","article-title":"A double blind study on azathioprine efficacy in multiple sclerosis: final report","volume":"240","author":"Milanese","year":"1993","journal-title":"Journal of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD015005.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1136\/jnnp.70.3.413","article-title":"Azathioprine and interferon beta-1b treatment in relapsing-remitting multiple sclerosis","volume":"70","author":"Milanese","year":"2001","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD015005.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1191\/135248506ms1307cr","article-title":"Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosis","volume":"12","author":"Putzki","year":"2006","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/jnnp.36.1.124","article-title":"Long-term treatment of multiple sclerosis with azathioprine","volume":"36","author":"Swinburn","year":"1973","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD015005.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1177\/1352458506070665","article-title":"Serum immunologic markers in multiple sclerosis patients on continuous combined therapy with beta-interferon 1a, prednisone and azathioprine","volume":"12","author":"Braun Hashemi","year":"2006","journal-title":"Multiple Sclerosis"},{"issue":"2","key":"10.1002\/14651858.CD015005.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1600-0404.1987.tb07899.x","article-title":"Azathioprine reduces intrathecal IgG synthesis in multiple sclerosis","volume":"75","author":"Caputo","year":"1987","journal-title":"Acta Neurologica Scandinavica"},{"issue":"4","key":"10.1002\/14651858.CD015005.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1159\/000113395","article-title":"Lesion load quantification in serial MR of early relapsing multiple sclerosis patients in azathioprine treatment. A retrospective study","volume":"38","author":"Cavazzuti","year":"1997","journal-title":"European Neurology"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1600-0404.1971.tb07480.x","article-title":"Therapeutic trial of Imuran (azathioprine) in multiple sclerosis","volume":"47","author":"Cendrowski","year":"1971","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1749-6632.1984.tb14806.x","article-title":"Therapeutic trials in multiple sclerosis: azathioprine","volume":"436","author":"Ellison","year":"1984","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"8371","key":"10.1002\/14651858.CD015005.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/s0140-6736(84)90145-4","article-title":"Not so benign long-term immunosupression in multiple sclerosis?","volume":"1","author":"Lhermitte","year":"1984","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD015005.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1212\/01.wnl.0000071218.34009.af","article-title":"Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b","volume":"60","author":"Markovic-Plese","year":"2003","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/s0140-6736(80)92107-8","article-title":"Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis","volume":"2","author":"Mertin","year":"1980","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/s0140-6736(82)90547-5","article-title":"Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report","volume":"2","author":"Mertin","year":"1982","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD015005.pub2-BIB0034|cit34","first-page":"285","article-title":"Treatment of multiple sclerosis with levamisole and azathioprine. Comparison of the effectiveness, of an 'immunostimulative' and 'immunosuppressive' treatment (author's translation)","volume":"49","author":"Patzold","year":"1978","journal-title":"Nervenarzt"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/0022-510x(82)90201-5","article-title":"Azathioprine in treatment of multiple sclerosis: final results of a controlled study of its effectiveness covering 115 patients","volume":"54","author":"Patzold","year":"1982","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/BF00313173","article-title":"Azathioprine in multiple sclerosis - a 3 year controlled study of its effectiveness","volume":"223","author":"Patzold","year":"1980","journal-title":"Journal of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD015005.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1177\/1352458508099476","article-title":"Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis","volume":"15","author":"Ravnborg","year":"2009","journal-title":"Multiple Sclerosis"},{"issue":"7889","key":"10.1002\/14651858.CD015005.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/s0140-6736(74)90866-6","article-title":"Intensive immunosuppression in the treatment of multiple sclerosis","volume":"2","author":"Ring","year":"1974","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/jnnp.42.4.338","article-title":"Prolonged azathioprine treatment of non-remitting multiple sclerosis","volume":"42","author":"Rosen","year":"1979","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000117351","article-title":"Cyclosporine versus azathioprine in the treatment of multiple sclerosis: 12-month clinical and immunological evaluation","volume":"30","author":"Steck","year":"1990","journal-title":"European Neurology"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1159\/000115838","article-title":"Follow-up evaluation after at least two years' treatment with azathioprine in a double-blind trial","volume":"24","author":"Zeeberg","year":"1985","journal-title":"European Neurology"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/978-94-009-4143-4_9","volume-title":"Multiple Sclerosis Research in Europe","author":"Zeeberg","year":"1986"},{"issue":"3","key":"10.1002\/14651858.CD015005.pub2-BIB0043|cit43","first-page":"215-22","article-title":"Treatment of multiple sclerosis by azathioprine. About 77 cases studied during 10 years (author's translation)]","volume":"134","author":"Aimard","year":"1978","journal-title":"Revue Neurologique"},{"issue":"3","key":"10.1002\/14651858.CD015005.pub2-BIB0044|cit44","first-page":"101-2","article-title":"Treatment of multiple sclerosis with azathioprine (Imuran)","volume":"29","author":"Ciesielski","year":"1974","journal-title":"Polski Tygodnik Lekarski"},{"issue":"10","key":"10.1002\/14651858.CD015005.pub2-BIB0045|cit45","first-page":"595","article-title":"Computerized analysis of 349 multiple sclerosis cases. Natural history of the disease. Evaluation of a continuous immunosuppressive therapeutic trial with azathioprine","volume":"243","author":"Confavreux","year":"1980","journal-title":"Lyon Medical"},{"issue":"48","key":"10.1002\/14651858.CD015005.pub2-BIB0046|cit46","first-page":"4704","article-title":"D penicillamine in the treatment of multiple sclerosis","volume":"23","author":"Danielczyk","year":"1973","journal-title":"Therapiewoche"},{"issue":"4","key":"10.1002\/14651858.CD015005.pub2-BIB0047|cit47","first-page":"147","article-title":"Immunologic aspects of azathioprine and steroid treatment of multiple sclerosis","volume":"31","author":"Ellison","year":"1981","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD015005.pub2-BIB0048|cit48","first-page":"221","article-title":"[Immunosuppressive therapy of multiple sclerosis. 1. Preliminary communication on the results of treatment with azathioprine and anti-lymphocytic globulin]","volume":"113","author":"Frick","year":"1971","journal-title":"Munchener Medizinische Wochenschrift"},{"issue":"45","key":"10.1002\/14651858.CD015005.pub2-BIB0049|cit49","first-page":"1987","article-title":"Immunsuppressive treatment of multiple sclerosis. 2. Critical review of general results (author's translation)","volume":"116","author":"Frick","year":"1974","journal-title":"Munchener Medizinische Wochenschrift"},{"issue":"48","key":"10.1002\/14651858.CD015005.pub2-BIB0050|cit50","first-page":"2105","article-title":"Immunosuppressive treatment of multiple sclerosis. 3. Results of treatment with azathioprine and antilymphocytic globulin (author's translation)","volume":"116","author":"Frick","year":"1974","journal-title":"Munchener Medizinische Wochenschrift"},{"issue":"35","key":"10.1002\/14651858.CD015005.pub2-BIB0051|cit51","first-page":"1111","article-title":"Immunosuppressive treatment of multiple sclerosis. 4. Results of treatment with azathioprine and antilymphocyte globulin (author's translation)","volume":"119","author":"Frick","year":"1977","journal-title":"Munchener Medizinische Wochenschrift"},{"issue":"6","key":"10.1002\/14651858.CD015005.pub2-BIB0052|cit52","first-page":"726","article-title":"Preliminary clinical experiences obtained with immunological therapy of multiple sclerosis","volume":"14","author":"Gentile","year":"1972","journal-title":"Annali Sclavo"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0053|cit53","first-page":"345\u20136","volume-title":"Recent Advances in Multiple Sclerosis Therapy","author":"Ghezzi","year":"1989"},{"issue":"41","key":"10.1002\/14651858.CD015005.pub2-BIB0054|cit54","first-page":"1955","article-title":"[Immunosuppressive therapy of multiple sclerosis using cyclophosphamide and imuran. Report on 57 cases]","volume":"27","author":"G\u00f6pel","year":"1972","journal-title":"Das Deutsche Gesundheitswesen"},{"issue":"9","key":"10.1002\/14651858.CD015005.pub2-BIB0055|cit55","first-page":"S250","article-title":"Cancer risk in a MS population treated with immunosuppressants","volume":"15","author":"Handouk","year":"2009","journal-title":"Multiple Sclerosis"},{"issue":"37","key":"10.1002\/14651858.CD015005.pub2-BIB0056|cit56","first-page":"2419","article-title":"Letter: Teratogenic effects of medications","volume":"3","author":"Hervet","year":"1974","journal-title":"Nouvelle Presse Medicale"},{"issue":"1","key":"10.1002\/14651858.CD015005.pub2-BIB0057|cit57","first-page":"148","article-title":"Efficacy and adverse effects of immunosuppressive therapy in diseases of the encephalomyelitis disseminata type (multiple sclerosis)","volume":"123","author":"Hitzchke","year":"1979","journal-title":"Zentralblatt fur Allgemeine Pathologie und Pathologische Anatomie"},{"issue":"10","key":"10.1002\/14651858.CD015005.pub2-BIB0058|cit58","first-page":"553","article-title":"[Prolonged treatment of multiple sclerosis with average doses of azathioprine. An evaluation of 15 years' experience]","volume":"140","author":"Lhermitte","year":"1984","journal-title":"Revue Neurologique"},{"issue":"24","key":"10.1002\/14651858.CD015005.pub2-BIB0059|cit59","first-page":"670-2","article-title":"Efficacy and tolerance of cyclosporin A in the treatment of multiple sclerosis","volume":"80","author":"Schluep","year":"1991","journal-title":"Schweizerische Rundschau fur Medizin Praxis."},{"issue":"3","key":"10.1002\/14651858.CD015005.pub2-BIB0060|cit60","first-page":"no. 4245","article-title":"Azathioprine therapy effects on antimyelin and other antibodies in multiple sclerosis","volume":"34","author":"Wilkerson","year":"1975","journal-title":"Federation Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD015005.pub2-BIB0061|cit61","first-page":"135","article-title":"Combined immunosuppressive treatment of multiple sclerosis with azathioprine and prednisolone F","volume":"19","author":"Yankov","year":"1980","journal-title":"Vatrechni Bolesti"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0062|cit62","unstructured":"M.A.I.N. trial www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-004937-13\/IT"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0063|cit63","unstructured":"Disease modifying therapies withdrawal in inactive secondary progressive multiple sclerosis patients older than 50 years (STOP-I-SEP) clinicaltrials.gov\/ct2\/show\/NCT03653273"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0064|cit64","unstructured":"Clinical and imaging patterns of neuroinflammation diseases in China (CLUE) clinicaltrials.gov\/ct2\/show\/NCT04106830"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0065|cit65","unstructured":"Drugs with well-established use in the treatment of neurological disorders for indications other than those covered by the marketing authorisation order www.aifa.gov.it\/documents\/20142\/1288746\/Allegato-4_Neurologia_04.01.2021.pdf\/7d0f6888-c49f-488b-25c7-03fe0d788484"},{"issue":"2","key":"10.1002\/14651858.CD015005.pub2-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1212\/01.wnl.0000316802.35974.34","article-title":"Temporal trends in the incidence of multiple sclerosis: a systematic review","volume":"71","author":"Alonso","year":"2008","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1212\/WNL.43.4.831","article-title":"Long-term safety of azathioprine therapy in multiple sclerosis","volume":"43","author":"Amato","year":"1993","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD015005.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S1474-4422(20)30277-5","article-title":"Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues","volume":"19","author":"Benedict","year":"2020","journal-title":"Lancet. Neurology"},{"issue":"2","key":"10.1002\/14651858.CD015005.pub2-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD015005.pub2-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.trecan.2020.02.021","article-title":"RAC1 as a therapeutic target in malignant melanoma","volume":"6","author":"Cannon","year":"2020","journal-title":"Trends in Cancer"},{"issue":"9313","key":"10.1002\/14651858.CD015005.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","article-title":"Multiple sclerosis","volume":"359","author":"Compston","year":"2002","journal-title":"Lancet"},{"issue":"20","key":"10.1002\/14651858.CD015005.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"1430\u20138","DOI":"10.1056\/NEJM200011163432001","article-title":"Relapses and progression of disability in multiple sclerosis","volume":"343","author":"Confavreux","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0074|cit74","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD015005.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"177\u201388","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/j.1749-6632.1993.tb35897.x","article-title":"The George Hitchings and Gertrude Elion lecture. The pharmacology of azathioprine","volume":"685","author":"Elion","year":"1993","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0077|cit77","unstructured":"Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis; 26 March 2015 www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-multiple-sclerosis_en-0.pdf"},{"issue":"6","key":"10.1002\/14651858.CD015005.pub2-BIB0078|cit78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008933.pub2","article-title":"Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis","author":"Filippini","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD015005.pub2-BIB0079|cit79","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012200.pub2","article-title":"Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis","author":"Filippini","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD015005.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"269\u201385","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"GBD 2016 Multiple Sclerosis Collaborators","year":"2019","journal-title":"Lancet. Neurology"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"189\u201394","DOI":"10.1007\/s40120-018-0112-1","article-title":"European and American guidelines for multiple sclerosis treatment","volume":"7","author":"Ghezzi","year":"2018","journal-title":"Neurology and Therapy"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0082|cit82","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2023"},{"issue":"1","key":"10.1002\/14651858.CD015005.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.25119","article-title":"B cell therapy for multiple sclerosis: entering an era","volume":"83","author":"Greenfield","year":"2018","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0085|cit85","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0086|cit86","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD015005.pub2-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jns.2004.04.022","article-title":"Clinical practice of immunosuppressive treatments in MS: results of a second international questionnaire","volume":"223","author":"Hommes","year":"2004","journal-title":"Journal of the Neurological Sciences"},{"issue":"2","key":"10.1002\/14651858.CD015005.pub2-BIB0088|cit88","first-page":"325","article-title":"Azathioprine","volume":"10","author":"Huskisson","year":"1984","journal-title":"Clinical Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD015005.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2174\/138955708785132756","article-title":"Azathioprine in multiple sclerosis","volume":"8","author":"Invernizzi","year":"2008","journal-title":"Mini-Reviews in Medicinal Chemistry"},{"issue":"5","key":"10.1002\/14651858.CD015005.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/1756285610379885","article-title":"Chemotherapeutics in the treatment of multiple sclerosis","volume":"3","author":"Kieseier","year":"2010","journal-title":"Therapeutics Advances in Neurological Disorders"},{"issue":"11","key":"10.1002\/14651858.CD015005.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2174\/157015911796557939","article-title":"Toxicities of immunosuppressive treatment of autoimmune neurologic diseases","volume":"9","author":"Lallana","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1177\/1352458511431076","article-title":"Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)","volume":"18","author":"Langdon","year":"2012","journal-title":"Multiple Sclerosis"},{"issue":"9","key":"10.1002\/14651858.CD015005.pub2-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1177\/13524585211030207","article-title":"Ethical use of off-label disease-modifying therapies for multiple sclerosis","volume":"27","author":"Laurson-Doube","year":"2021","journal-title":"Multiple Sclerosis"},{"issue":"3","key":"10.1002\/14651858.CD015005.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"193","DOI":"10.5217\/ir.2015.13.3.193","article-title":"Use of thiopurines in inflammatory bowel disease: a Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID)","volume":"13","author":"Lee","year":"2015","journal-title":"Intestinal Research"},{"issue":"8371","key":"10.1002\/14651858.CD015005.pub2-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/s0140-6736(84)90145-4","article-title":"Not so benign long-term immunosuppression in multiple sclerosis?","volume":"1","author":"Lhermitte","year":"1984","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD015005.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1212\/wnl.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in multiple sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD015005.pub2-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"278\u201386","DOI":"10.1212\/wnl.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD015005.pub2-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/s0303-8467(02)00035-5","article-title":"Compartmentalization of the immune response in the central nervous system and natural history of multiple sclerosis. Implications for therapy","volume":"104","author":"Massacesi","year":"2002","journal-title":"Clinical Neurology and Neurosurgery"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0100|cit100","volume-title":"Multiple Sclerosis: A Reappraisal","author":"McAlpine","year":"1968"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/oxfordjournals.bmb.a071393","article-title":"Diagnosis and classification of multiple sclerosis","volume":"33","author":"McDonald","year":"1977","journal-title":"British Medical Bulletin"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD015005.pub2-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0104|cit104","unstructured":"McKenzie JE Brennan SE Ryan RE Thomson HJ Johnston RV Thomas J Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD015005.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/practneurol-2018-002161","article-title":"Azathioprine and the neurologist","volume":"20","author":"McWilliam","year":"2020","journal-title":"Practical Neurology"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1471-2377-14-58","article-title":"Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis","volume":"14","author":"Meyer-Moock","year":"2014","journal-title":"BMC Neurology"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0107|cit107","unstructured":"Microsoft Excel Microsoft Corporation 2024"},{"issue":"10","key":"10.1002\/14651858.CD015005.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1474-4422(07)70243-0","article-title":"Primary-progressive multiple sclerosis","volume":"6","author":"Miller","year":"2007","journal-title":"Lancet. Neurology"},{"issue":"6","key":"10.1002\/14651858.CD015005.pub2-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"1144\u201352","DOI":"10.1016\/j.jaad.2015.12.044","article-title":"High azathioprine dose and lip cancer risk in liver, heart, and lung transplant recipients: a population-based cohort study","volume":"74","author":"Na","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0110|cit110","unstructured":"NCI's dictionary of cancer terms: short-term side effect www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/short-term-side-effect"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"Journal of Clinical Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD015005.pub2-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"1296\u2013305","DOI":"10.1093\/aje\/kws375","article-title":"Use of azathioprine and the risk of cancer in inflammatory bowel disease","volume":"177","author":"Pasternak","year":"2013","journal-title":"American Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD015005.pub2-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1212\/WNL.0000000000001094","article-title":"Relapses and disability accumulation in progressive multiple sclerosis","volume":"84","author":"Paz Sold\u00e1n","year":"2015","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0114|cit114","unstructured":"Peryer G Golder S Junqueira D Vohra S Loke YK Chapter 19: Adverse effects. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from training.cochrane.org\/handbook"},{"issue":"10","key":"10.1002\/14651858.CD015005.pub2-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry","volume":"61","author":"Peters","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD015005.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Annals of Neurology"},{"issue":"17","key":"10.1002\/14651858.CD015005.pub2-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/wnl.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0118|cit118","unstructured":"Reeves BC Deeks JJ Higgins JP Shea B Tugwell P Wells GA Chapter 24: Including non-randomized studies on intervention effects. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0119|cit119","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2020"},{"issue":"2","key":"10.1002\/14651858.CD015005.pub2-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"231\u20136","DOI":"10.1007\/s00415-005-0965-y","article-title":"Glatiramer acetate induces pro\u2013apoptotic mechanisms involving Bcl\u20132, Bax and Cyt\u2013c in peripheral lymphocytes from multiple sclerosis patient","volume":"253","author":"Ruggieri","year":"2005","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0121|cit121","first-page":"99","article-title":"Clinical and hematologic study of 6[(1-methyl-4-nitro-5-imidazolyl)-thio] purine (B.W. 57-322) and related compounds","volume":"14","author":"Rundles","year":"1961","journal-title":"Cancer Chemotherapy Reports"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1749-6632.1965.tb20235.x","article-title":"Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis","volume":"122","author":"Schumacher","year":"1965","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD015005.pub2-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1172\/JCI16432","article-title":"CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes","volume":"111","author":"Tiede","year":"2003","journal-title":"Journal of Clinical Investigation"},{"issue":"9","key":"10.1002\/14651858.CD015005.pub2-BIB0125|cit125","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011381.pub2","article-title":"Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis","author":"Tramacere","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD015005.pub2-BIB0126|cit126","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012186.pub2","article-title":"Adverse effects of immunotherapies for multiple sclerosis: a networkmeta-analysis","author":"Tramacere","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD015005.pub2-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nrneurol.2016.188","article-title":"Treatment decisions in multiple sclerosis\u2014insights from real-world observational studies","volume":"13","author":"Trojano","year":"2017","journal-title":"Nature Reviews Neurology"},{"issue":"3","key":"10.1002\/14651858.CD015005.pub2-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/BF02260859","article-title":"A health-related quality of life measure for multiple sclerosis","volume":"4","author":"Vickrey","year":"1995","journal-title":"Quality of Life Research"},{"issue":"14","key":"10.1002\/14651858.CD015005.pub2-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"5","key":"10.1002\/14651858.CD015005.pub2-BIB0130|cit130","first-page":"651","article-title":"Mercaptopurine pharmaco-genetics: monogenic inheritance of erythrocyte thiopurine methyl-transferase activity","volume":"32","author":"Weinshilboum","year":"1980","journal-title":"American Journal of Human Genetics"},{"key":"10.1002\/14651858.CD015005.pub2-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"101459","DOI":"10.1016\/j.msard.2019.101459","article-title":"Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to The MENACTRIMS Guidelines","volume":"37","author":"Yamout","year":"2019","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"1","key":"10.1002\/14651858.CD015005.pub2-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"205521731984846","DOI":"10.1177\/2055217319848466","article-title":"Treatment of multiple sclerosis in special populations: the case of refugees","volume":"6","author":"Zeineddine","year":"2020","journal-title":"Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"},{"issue":"1","key":"10.1002\/14651858.CD015005.pub2-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"163\u201371","DOI":"10.1007\/s004410000179","article-title":"Apoptosis in multiple sclerosis","volume":"301","author":"Zipp","year":"2000","journal-title":"Cell and Tissue Research"},{"issue":"4","key":"10.1002\/14651858.CD015005.pub2-BIB0134|cit134","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003982.pub2","article-title":"Azathioprine for multiple sclerosis","author":"Casetta","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD015005.pub2-BIB0135|cit135","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015005","article-title":"Azathioprine for people with multiple sclerosis","author":"Nonino","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:48:22Z","timestamp":1777456102000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015005.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":135,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015005.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,9]]}}}